(Q24234800)

PubMed

23 October 2023

Dan H Moore

2

Dan H

Moore

1 reference

PubMed

20556761

23 October 2023

Richard S Bedlack

series ordinal

3

author given names

Richard S

author last names

Bedlack

1 reference

PubMed

20556761

Cochrane Database of Systematic Reviews

23 October 2023

publication date

16 June 2010

0 references

published in

0 references

cites work

A randomized sequential trial of creatine in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

A clinical trial of creatine in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

The creatine-creatine phosphate energy shuttle

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

Prognosis in amyotrophic lateral sclerosis: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

No effect of creatine on respiratory distress in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

Bipap improves survival and rate of pulmonary function decline in patients with ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

Direct antioxidant properties of creatine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

Comparison of sporadic and familial disease amongst 580 cases of motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

The epidemiology of ALS in Modena, Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

Survival of patients with amyotrophic lateral sclerosis in a population-based registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

Factors associated with survival in the National Registry of Veterans with ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

Recent advances in amyotrophic lateral sclerosis research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

Amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

Functional outcome measures as clinical trial endpoints in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

The epidemiology of motor neuron diseases: a review of recent studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

7 January 2021

Amyotrophic lateral sclerosis: early predictors of prolonged survival

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

7 January 2021

Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary function

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

7 January 2021

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

7 January 2021

Regression Models and Life-Tables (with discussion)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

7 January 2021

A simple analysis of the "phosphocreatine shuttle"

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

7 January 2021

Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005225.PUB2

7 January 2021

10.1002/14651858.CD005225.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_cmqzcyjj7rdgtgmi6x73v6o6zy

0 references